New approaches in the management of chronic hepatitis B: role of tenofovir

References

• de FranchisR HALauGLavanchyDLokAMcIntyreNMeleAEASL International Consensus Conference on Hepatitis B. 13–14 September, 2002 Geneva, Switzerland. Consensus statement (long version)J Hepatol200339Suppl 1S3S2514708673
   PubMed Web of Science ®Google Scholar
• KaneMGlobal programme for control of hepatitis B infectionVaccine199513Suppl 1S47S497571830
   PubMed Web of Science ®Google Scholar
• StevensCEBeasleyRPTsuiJLeeWCVertical transmission of hepatitis B antigen in TaiwanN Engl J Med1975292157717741113797
   PubMed Web of Science ®Google Scholar
• TassopoulosNCPapaevangelouGJSjogrenMHRoumeliotou-KarayannisAGerinJLPurcellRHNatural history of acute hepatitis B surface antigen-positive hepatitis in Greek adultsGastroenterology1987926184418503569758
   PubMed Web of Science ®Google Scholar
• BortolottiFCadrobbiPCrivellaroCGuidoMRuggeMNoventaFLong-term outcome of chronic type B hepatitis in patients who acquire hepatitis B virus infection in childhoodGastroenterology19909938058102379783
   PubMed Web of Science ®Google Scholar
• FattovichGRuggeMBrolloLPontissoPNoventaFGuidoMClinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type BHepatology1986621671723957228
   PubMed Web of Science ®Google Scholar
• LiawYFChuCMSuIJHuangMJLinDYChang-ChienCSClinical and histological events preceding hepatitis B e antigen seroconversion in chronic type B hepatitisGastroenterology19838422162196848402
   PubMed Web of Science ®Google Scholar
• HsuYSChienRNYehCTSheenISChiouHYChuCMLong-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis BHepatology20023561522152712029639
   PubMed Web of Science ®Google Scholar
• MannoMCammaCSchepisFBassiFGelminiRGianniniFNatural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 yearsGastroenterology2004127375676315362032
   PubMed Web of Science ®Google Scholar
• BuckwoldVEXuZChenMYenTSOuJHEffects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replicationJ Virol1996709584558518709203
   PubMed Web of Science ®Google Scholar
• CarmanWFJacynaMRHadziyannisSKarayiannisPMcGarveyMJMakrisAMutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infectionLancet1989286635885892570285
   PubMed Web of Science ®Google Scholar
• BrunettoMROliveriFCocoBLeandroGColombattoPGorinJMOutcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort studyJ Hepatol200236226327011830339
   PubMed Web of Science ®Google Scholar
• LokASMcMahonBJChronic hepatitis BHepatology2007 2645250753917256718
   PubMed Web of Science ®Google Scholar
• KimHCNamCMJeeSHHanKHOhDKSuhINormal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort studyBMJ2004328744698315028636
   PubMed Web of Science ®Google Scholar
• LaiMHyattBJNasserICurryMAfdhalNHThe clinical significance of persistently normal ALT in chronic hepatitis B infectionJ Hepatol200747676076717928090
   PubMed Web of Science ®Google Scholar
• PapatheodoridisGVChrysanthosNHadziyannisECholongitasEManesisEKLongitudinal changes in serum HBV DNA levels and predictors of progression during the natural course of HBeAg-negative chronic hepatitis B virus infectionJ Viral Hepat200815643444118194171
   PubMed Web of Science ®Google Scholar
• ChenCJYangHISuJJenCLYouSLLuSNRisk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA levelJAMA20062951657316391218
   PubMed Web of Science ®Google Scholar
• IloejeUHYangHISuJJenCLYouSLChenCJPredicting cirrhosis risk based on the level of circulating hepatitis B viral loadGastroenterology2006130367868616530509
   PubMed Web of Science ®Google Scholar
• ChangTTGishRGde ManRGadanoASollanoJChaoYCA comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis BN Engl J Med2006354101001101016525137
   PubMed Web of Science ®Google Scholar
• DienstagJLSchiffERWrightTLPerrilloRPHannHWGoodmanZLamivudine as initial treatment for chronic hepatitis B in the United StatesN Engl J Med1999341171256126310528035
   PubMed Web of Science ®Google Scholar
• HadziyannisSJTassopoulosNCHeathcoteEJChangTTKitisGRizzettoMAdefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis BN Engl J Med2003348980080712606734
   PubMed Web of Science ®Google Scholar
• HeathcoteEJGaneEDe ManRLeeSFlisiakRMannsMA randomized, double-blind, comparison of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAg-positive chronic hepatitis B (CHB)Hepatology200746S861A
   Web of Science ®Google Scholar
• JanssenHLvan ZonneveldMSenturkHZeuzemSAkarcaUSCakalogluYPegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trialLancet2005365945412312915639293
   PubMed Web of Science ®Google Scholar
• LaiCLChienRNLeungNWChangTTGuanRTaiDIA one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study GroupN Engl J Med199879339261689654535
   PubMed Web of Science ®Google Scholar
• LaiCLGaneELiawYFHsuCWThongsawatSWangYTelbivudine versus lamivudine in patients with chronic hepatitis BN Engl J Med2007357252576258818094378
   PubMed Web of Science ®Google Scholar
• LaiCLShouvalDLokASChangTTCheinquerHGoodmanZEntecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis BN Engl J Med2006354101011102016525138
   PubMed Web of Science ®Google Scholar
• LauGKPiratvisuthTLuoKXMarcellinPThongsawatSCooksleyGPeginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis BN Engl J Med2005352262682269515987917
   PubMed Web of Science ®Google Scholar
• MarcellinPButiMKrastevZGermanidisGKaitaKKotzevIA randomized, double-blind, comparison of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAg-negative chronic hepatitis B (CHB)Hepatology200746S290AS291A
   Web of Science ®Google Scholar
• MarcellinPChangTTLimSGTongMJSievertWShiffmanMLAdefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis BN Engl J Med2003348980881612606735
   PubMed Web of Science ®Google Scholar
• MarcellinPLauGKBoninoFFarciPHadziyannisSJinRPeginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis BN Engl J Med2004351121206121715371578
   PubMed Web of Science ®Google Scholar
• SorrellMFBelongiaEACostaJGareenIFGremJLInadomiJMNational Institutes of Health Consensus Development Conference Statement: Management of Hepatitis BAnn Int Med2009150210411019124811
   PubMed Web of Science ®Google Scholar
• PetersMActions of cytokines on the immune response and viral interactions: an overviewHepatology19962349099168666349
   PubMed Web of Science ®Google Scholar
• van NunenABHansenBESuhDJLohrHFChemelloLFontaineHDurability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferaseGut200352342042412584227
   PubMed Web of Science ®Google Scholar
• CooksleyWGPiratvisuthTLeeSDMahachaiVChaoYCTanwandeeTPeginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis BJ Viral Hepat200310429830512823597
   PubMed Web of Science ®Google Scholar
• NiederauCHeintgesTLangeSGoldmannGNiederauCMMohrLLong-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis BN Engl J Med199633422142214278618580
   PubMed Web of Science ®Google Scholar
• van ZonneveldMHonkoopPHansenBENiestersHGMuradSDde ManRALong-term follow-up of alpha-interferon treatment of patients with chronic hepatitis BHepatology200439380481014999700
   PubMed Web of Science ®Google Scholar
• BusterEHHansenBEButiMDelwaideJNiederauCMichielsenPPPeginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosisHepatology200746238839417604363
   PubMed Web of Science ®Google Scholar
• ZoulimFNew insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNAJ Hepatol200542330230815710212
   PubMed Web of Science ®Google Scholar
• ZoulimFPerrilloRHepatitis B: reflections on the current approach to antiviral therapyJ Hepatol200848Suppl 1S2S1918304680
   PubMed Web of Science ®Google Scholar
• Werle-LapostolleBBowdenSLocarniniSWursthornKPetersenJLauGPersistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapyGastroenterology200412671750175815188170
   PubMed Web of Science ®Google Scholar
• TsiangMGibbsCSAnalysis of hepatitis B virus dynamics and its impact on antiviral developmentMethods Mol Med20049636137714762282
   PubMedGoogle Scholar
• WursthornKLutgehetmannMDandriMVolzTBuggischPZollnerBPeginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis BHepatology200644367568416941693
   PubMed Web of Science ®Google Scholar
• LiawYFSungJJChowWCFarrellGLeeCZYuenHLamivudine for patients with chronic hepatitis B and advanced liver diseaseN Engl J Med2004 7351151521153115470215
   PubMed Web of Science ®Google Scholar
• NowakMABonhoefferSHillAMBoehmeRThomasHCMcDadeHViral dynamics in hepatitis B virus infectionProc Natl Acad Sci U S A1996939439844028633078
   PubMed Web of Science ®Google Scholar
• LocarniniSQiXArterburnSSnowABrosgartCCurrieGIncidence and and predictors of emergence of adefovir resistant HBV during 4 years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (CHB) (abstract)J Hepatol20054217
   Web of Science ®Google Scholar
• YuenMFSablonEHuiCKYuanHJDecraemerHLaiCLFactors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapyHepatology2001344Pt 178579111584376
   PubMed Web of Science ®Google Scholar
• KeeffeEBZeuzemSKoffRSDieterichDTEsteban-MurRGaneEJReport of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis BClin Gastroenterol Hepatol20075889089717632041
   PubMed Web of Science ®Google Scholar
• Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Delta Coordinating CommitteeLancet199634890232832918709686
   PubMed Web of Science ®Google Scholar
• BalzariniJHolyAJindrichJNaesensLSnoeckRScholsDDifferential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurineAntimicrob Agents Chemother19933723323388452366
   PubMed Web of Science ®Google Scholar
• ShawJPSueokoCMOliyaiRLeeWAArimilliMNKimCUMetabolism and pharmacokinetics of novel oral prodrugs of 9-(R)-2-(phosphonomethoxy)propyl. adenine (PMPA) in dogsPharm Res19971412182418299453075
   PubMed Web of Science ®Google Scholar
• DelaneyWEtRayASYangHQiXXiongSZhuYIntracellular metabolism and in vitro activity of tenofovir against hepatitis B virusAntimicrob Agents Chemother20065072471247716801428
   PubMed Web of Science ®Google Scholar
• van GelderJDefermeSNaesensLDe ClercqEvan den MooterGKingetRIntestinal absorption enhancement of the ester prodrug tenofovir disoproxil fumarate through modulation of the biochemical barrier by defined ester mixturesDrug Metab Dispos200230892493012124311
   PubMed Web of Science ®Google Scholar
• RobbinsBLSrinivasRVKimCBischofbergerNFridlandAAnti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethy lcarbonyl)PMPAAntimicrob Agents Chemother19984236126179517941
   PubMed Web of Science ®Google Scholar
• De ClercqEHolyAAcyclic nucleoside phosphonates: a key class of antiviral drugsNat Rev2005411928940
   Google Scholar
• KearneyBPFlahertyJFShahJTenofovir disoproxil fumarate: clinical pharmacology and pharmacokineticsClin Pharmacokinet200443959561215217303
   PubMed Web of Science ®Google Scholar
• Barditch-CrovoPDeeksSGCollierASafrinSCoakleyDFMillerMPhase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adultsAntimicrob Agents Chemother200145102733273911557462
   PubMed Web of Science ®Google Scholar
• HazraRBalisFMTullioANDeCarloEWorrellCJSteinbergSMSingle-dose and steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected childrenAntimicrob Agents Chemother200448112412914693529
   PubMed Web of Science ®Google Scholar
• BodsworthNJCooperDADonovanBThe influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier stateJ Infect Dis19911635113811402019762
   PubMed Web of Science ®Google Scholar
• KonopnickiDMocroftAde WitSAntunesFLedergerberBKatlamaCHepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohortAIDS200519659360115802978
   PubMed Web of Science ®Google Scholar
• Bani-SadrFPalmerPScieuxCMolinaJMNinety-six-week efficacy of combination therapy with lamivudine and tenofovir in patients coinfected with HIV-1 and wild-type hepatitis B virusClin Infect Dis20043971062106415472862
   PubMed Web of Science ®Google Scholar
• BenhamouYFleuryHTrimouletPPellegrinIUrbinelliRKatlamaCAnti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patientsHepatology200643354855516496322
   PubMed Web of Science ®Google Scholar
• de Vries-SluijsTEvan der EijkAAHansenBEOsterhausADde ManRAvan der EndeMEWild type and YMDD variant of hepatitis B virus: no difference in viral kinetics on lamivudine/tenofovir therapy in HIV-HBV co-infected patientsJ Clin Virol2006361606316418013
   PubMed Web of Science ®Google Scholar
• DoreGJCooperDAPozniakALDeJesusEZhongLMillerMDEfficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virusJ Infect Dis200418971185119215031786
   PubMed Web of Science ®Google Scholar
• GutierrezSGuillemiSJahnkeNMontessoriVHarriganPRMontanerJSTenofovir-based rescue therapy for advanced liver disease in 6 patients coinfected with HIV and hepatitis B virus and receiving lamivudineClin Infect Dis2008463e28e3018181733
   PubMed Web of Science ®Google Scholar
• JainMKComanorLWhiteCKipnisPElkinCLeungKTreatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with responseJ Viral Hepat200714317618217305883
   PubMed Web of Science ®Google Scholar
• LacombeKGozlanJBoellePYSerfatyLZoulimFValleronAJLong-term hepatitis B virus dynamics in HIV-hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarateAIDS200519990791515905671
   PubMed Web of Science ®Google Scholar
• LacombeKGozlanJBoydABoellePYBonnardPMolinaJMComparison of the antiviral activity of adefovir and tenofovir on hepatitis B virus in HIV-HBV-coinfected patientsAntivir Ther200813570571318771054
   PubMed Web of Science ®Google Scholar
• MatthewsGVAvihingsanonALewinSRAminJRerknimitrRPetcharapiratPA randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naive individuals in ThailandHepatology20084841062106918697216
   PubMed Web of Science ®Google Scholar
• MatthewsGVCooperDADoreGJImprovements in parameters of end-stage liver disease in patients with HIV/HBV-related cirrhosis treated with tenofovirAntivir Ther200712111912217503756
   PubMed Web of Science ®Google Scholar
• NelsonMPortsmouthSStebbingJAtkinsMBarrAMatthewsGAn open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individualsAIDS2003171F7F1012478090
   PubMed Web of Science ®Google Scholar
• NunezMPerez-OlmedaMDiazBRiosPGonzalez-LahozJSorianoVActivity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudineAIDS200216172352235412441815
   PubMed Web of Science ®Google Scholar
• PetersMGAndersenJLynchPLiuTAlston-SmithBBrosgartCLRandomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127Hepatology20064451110111617058225
   PubMed Web of Science ®Google Scholar
• Quiros-RoldanECalabresiALapadulaGTirelliVCostarelliSCologniGEvidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIVAntivir Ther200813334134818572746
   PubMed Web of Science ®Google Scholar
• RistigMBCrippinJAbergJAPowderlyWGLisker-MelmanMKesselsLTenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failedJ Infect Dis2002186121844184712447773
   PubMed Web of Science ®Google Scholar
• SchmutzGNelsonMLutzTSheldonJBrunoRvon BoemmelFCombination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfectionAIDS200620151951195416988516
   PubMed Web of Science ®Google Scholar
• StephanCBergerACarlebachALutzTBickelMKlaukeSImpact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virusJ Antimicrob Chemother20055661087109316269552
   PubMed Web of Science ®Google Scholar
• van BommelFWunscheTMaussSReinkePBergkASchurmannDComparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infectionHepatology20044061421142515565615
   PubMed Web of Science ®Google Scholar
• van der EijkAAHansenBENiestersHGJanssenHLvan de EndeMSchalmSWViral dynamics during tenofovir therapy in patients infected with lamivudine-resistant hepatitis B virus mutantsJ Viral Hepat200512436437215985006
   PubMed Web of Science ®Google Scholar
• HeathcoteEJGaneEDe ManRChanSSievertWMaussSTwo year tenofovir disoproxil fumarate (TDF) treatment and adefovir dipivoxil (ADV) switch data in HBeAg-positive patients with chronic hepatitis B (study 103), preliminary analysisHepatology200848Suppl 1A158
   Google Scholar
• HeathcoteEJGeorgeJGordonSCBronowickiJPSperlJWilliamsRTenofovir disoproxil fumarate (TDF) for the treatment of HBeAg-positive chronic hepatitis B: week 72 TDF data and week 24 adefovir dipivoxil switch data (study 103)J Hepatol200848Suppl 2A72
   Google Scholar
• MarcellinPButiMKrastevZGurelSBalabanskaRDusheikoGTwo year tenofovir disoproxil fumarate (TDF) treatment and adefovir dipivoxil (ADV) switch data in HBeAg-negative patients with chronic hepatitis B (study 102), preliminary analysisHepatology200848Suppl 1A146
   Google Scholar
• MarcellinPJacobsonIMHabersetzerFSenturkHAndreonePMoyesCTenofovir disoproxil fumarate (TDF) for the treatment of HBeAg-negative chronic hepatitis B: week 72 and week 24 adefovir dipivoxil switch data (study 102)J Hepatol200848Suppl 2A57
   Google Scholar
• LaiCLDienstagJSchiffELeungNWAtkinsMHuntCPrevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis BClin Infect Dis200336668769612627352
   PubMed Web of Science ®Google Scholar
• Van BommelFDe ManRErhardtAHuppeDSteinKBuggischPFirst multicenter evaluation of the efficacy of tenofovir in nucleos(t)ide analog experienced patients with HBV monoinfectionHepatology200746S270A
   Web of Science ®Google Scholar
• MannsMJeffersLDalekosGBergTTrepoCRobertsSThe antiviral response to tenofovir disoproxil fumarate (TDF) is comparable in lamivudine (LAM)-naive and LAM-experienced subjects treated for chronic hepatitis B (CHB)J Hepatol200848Suppl 2A74
   Google Scholar
• LeemansWFJanssenHLNiestersHGde ManRASwitching patients with lamivudine resistant chronic hepatitis B virus from tenofovir to adefovir results in less potent HBV-DNA suppressionJ Viral Hepat200815210811418184193
   PubMed Web of Science ®Google Scholar
• SchildgenOHartmannHGerlichWHReplacement of tenofovir with adefovir may result in reactivation of hepatitis B virus replicationScand J Gastroenterol200641224524616484132
   PubMed Web of Science ®Google Scholar
• van BommelFBergTReactivation of viral replication after replacement of tenofovir by adefovirHepatology200542123924015962310
   PubMed Web of Science ®Google Scholar
• van BommelFZollnerBSarrazinCSpenglerUHuppeDMollerBTenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapyHepatology200644231832516871563
   PubMed Web of Science ®Google Scholar
• Van BommelFDe ManRSteinKHuppeDPetersenJBuggischPA multicenter analysis of antiviral response after one year of tenofovir monotherapy in HBV-monoinfected patients with prior nucleos(t)ide analog experienceJ Hepatol200848Suppl 2A73
   Google Scholar
• Van BommelFTrojanJFeuchtHMollerBHuppeDWiedenmannBTenofovir shows limited efficay in treatment of HBV infections resistant against adefovirHepatology200746S664A
   Web of Science ®Google Scholar
• TanJDegertekinBWongSNHusainMOberhelmanKLokASTenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutationsJ Hepatol200848339139818199519
   PubMed Web of Science ®Google Scholar
• VilletSPichoudCVilleneuveJPTrepoCZoulimFSelection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patientGastroenterology200613141253126117030194
   PubMed Web of Science ®Google Scholar
• BergTMollerBTrinhHChanSMarcellinPSuarezETenofovir disoproxil fumarate (TDF) versus emtricitabine plus TDF for treatment of chronic hepatitis B (CHB) in subjects with persistent viral replication in receiving adefovir dipivoxil (ADV)J Hepatol200848Suppl 2A76
   Google Scholar
• ShermanMYurdaydinCSollanoJSilvaMLiawYFCianciaraJEntecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis BGastroenterology200613072039204916762627
   PubMed Web of Science ®Google Scholar
• LeemansWFNiestersHGvan der EijkAAJanssenHLSchalmSWde ManRASelection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovirEur J Gastroenterol Hepatol200820877377718617782
   PubMed Web of Science ®Google Scholar
• PanCHuKExcellent treatment response to tenofovir (TDF) monotherapy in chronic hepatitis B (CHB) patients with prior suboptimal response to entecavir (ETV) monotherapyHepatology200848Suppl 1A932
   Google Scholar
• ButiMHadziyannisSMathurinPUrbanekPShermanMStrasserSTenofovir disoproxil fumarate (TDF) is highly active for treatment of chronic hepatitis B in subjects with cirrhosisJ Hepatol200848Suppl 2A75
   Google Scholar
• SheldonJCaminoNRodesBBartholomeuszAKuiperMTackeFSelection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovirAntivir Ther200510672773416218172
   PubMed Web of Science ®Google Scholar
• FungSKMazzulliTShermanMPopovicVSablonEPresence of rtA194T mutation at baseline does not reduce efficacy to tenofovir (TDF) in patients iwth lamivudine(LAM)-resistant chronic hepatitis BHepatology200848Suppl 1A880
   Google Scholar
• Amini-Bavil-OlyaeeSSheldonJTrautweinCTackeFPrecore and basal core promotor mutation restore the reduced replication efficacy of tenofovir-resistance associated rtA194T polymerase mutations of the hepatitis B virusHepatology200848Suppl 1A842
   Google Scholar
• BrunelleMNJacquardACPichoudCDurantelDCarrouee-DurantelSVilleneuveJPSusceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovirHepatology20054161391139815915463
   PubMed Web of Science ®Google Scholar
• BrunelleMNLuciforaJNeytsJVilletSHolyATrepoCIn vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutantsAntimicrob Agents Chemother20075162240224317371827
   PubMed Web of Science ®Google Scholar
• QiXXiongSYangHMillerMDelaneyWEtIn vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agentsAntivir Ther200712335536217591025
   PubMed Web of Science ®Google Scholar
• VilletSPichoudCBillioudGBarraudLDurantelSTrepoCImpact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failureJ Hepatol200848574775518331765
   PubMed Web of Science ®Google Scholar
• SnowAChappellBCurtisMZhuYHeathcoteEJMarcellinPWeek 96 resistance surveillance for HBeAg-positive and negative subjects with chronic HBV infection randomized to receive tenofovir DF 300 mg QDHepatology200848suppl 1A977
   Google Scholar
• SnowASorbelJChappellBCurtisMZhuYBorroto-EsodaKLack of tenofovir DF (TDF) resistance mutations in treatment-naive and treatment-experienced subjects with chronic HBV infection following 48 weeks of TDF monotherapyEASL conference Hepatitis B and C virus: resistance to antiviral therapyParis, France2008
   Google Scholar
• ViganoMLamperticoPIavaroneMTontiniGFacchettiFColomboMHigh risk of renal impairment and arterial hypertension during long-term adefovir and lamivudine combination therapy in patients with lamivudine-resistant chronic hepatitis BHepatology200848Suppl 1A897
   Google Scholar
• CocaSPerazellaMARapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicityAm J Med Sci2002324634234412495304
   PubMed Web of Science ®Google Scholar
• KarrasALafaurieMFurcoABourgaritADrozDSereniDTenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidusClin Infect Dis20033681070107312684922
   PubMed Web of Science ®Google Scholar
• RollotFNazalEMChauvelot-MoachonLKelaidiCDanielNSabaMTenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome: the role of lopinavir-ritonavir-didanosineClin Infect Dis20033712e174e17614689363
   PubMed Web of Science ®Google Scholar
• GallantJEParishMAKerulyJCMooreRDChanges in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatmentClin Infect Dis20054081194119815791522
   PubMed Web of Science ®Google Scholar
• JonesRStebbingJNelsonMMoyleGBowerMMandaliaSRenal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case-control studyJ Acquir Immune Defic Syndr20043741489149515602127
   PubMed Web of Science ®Google Scholar
• NelsonMRKatlamaCMontanerJSCooperDAGazzardBClotetBThe safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 yearsAIDS200721101273128117545703
   PubMed Web of Science ®Google Scholar
• ReislerRBMurphyRLRedfieldRRParkerRAIncidence of pancreatitis in HIV-1-infected individuals enrolled in 20 adult AIDS clinical trials group studies: lessons learnedJ Acquir Immune Defic Syndr200539215916615905731
   PubMed Web of Science ®Google Scholar
• GallantJEStaszewskiSPozniakALDeJesusESuleimanJMMillerMDEfficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trialJAMA2004292219120115249568
   PubMed Web of Science ®Google Scholar